CD9 and hematopoietic and lymphoid system neoplasm: In our cohort, following four vaccine doses, 90% (72/80) of patients with blood cancer had detectable NAbT against BA.2, which was higher than the proportion with NAb against BA.1 (McNemar test, p = 0.008) (Figure 1B).